6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM

The Department of Veterans Affairs National Acquisition Center is seeking to procure Fluticasone Propionate 50 MCG/Spray Nasal Solution in 16GM bottles containing 120 doses/sprays through a firm-fixed-price, indefinite-delivery requirements contract. The solicitation is structured for a base year with four optional one-year extensions, targeting pharmaceutical manufacturers capable of meeting stringent requirements. Offerors must possess FDA approval, current Good Manufacturing Practice (cGMP) certification, and unique NDC numbers. The contract will be awarded to the lowest-priced technically acceptable offer that satisfies all specified criteria. Proposals are due by March 13, 2025, at 2:30 PM CT, and must be submitted via email to michael.olszewski@va.gov and diana.martinez1@va.gov.

The procurement is not set aside for any specific business size, making it open to all qualified pharmaceutical manufacturers. The estimated annual quantity is 5,784,828 bottles, distributed across multiple federal agencies including VA (3,992,460 bottles), DoD (1,448,719 bottles), Bureau of Prisons (13,528 bottles), and Indian Health Service (330,121 bottles). Contractors must establish business agreements with pharmaceutical prime vendors McKesson and Cencora and include a 0.5% Cost Recovery Fee in their pricing. Large businesses bidding on contracts valued over $750,000 are required to submit a subcontracting plan. The contract will leverage the Pharmaceutical Preparation Manufacturing NAICS code 325412 and the Drugs and Biologicals PSC category 6505, indicating a comprehensive approach to pharmaceutical procurement for federal healthcare systems.